Organigram (NASDAQ:OGI - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Tuesday, February 11th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $48.94 million for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.
Organigram (NASDAQ:OGI - Get Free Report) last released its quarterly earnings results on Wednesday, December 18th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.01). Organigram had a negative net margin of 28.58% and a negative return on equity of 11.68%. On average, analysts expect Organigram to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Organigram Price Performance
Organigram stock traded up $0.02 during midday trading on Friday, reaching $1.68. The stock had a trading volume of 1,246,525 shares, compared to its average volume of 652,664. The firm's fifty day simple moving average is $1.56 and its two-hundred day simple moving average is $1.67. Organigram has a twelve month low of $1.31 and a twelve month high of $2.91. The firm has a market cap of $211.94 million, a price-to-earnings ratio of -4.42 and a beta of 1.00.
About Organigram
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Featured Articles
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
